Immodulon is dedicated to the development of novel, safe and effective treatments for cancer patients. To date, IMM-101 has been tested mostly in metastatic cancer patients with diagnoses including Melanoma, Colorectal and Pancreatic cancers.
We believe IMM-101 can become a backbone immunotherapy across multiple tumour types in combination with any of the four major pillars of cancer therapy: immunotherapy, chemotherapy, radio/ablation therapy and surgery. IMM-101’s mechanism of action should not only make it applicable to a range of different cancers, but it is also expected that it will enhance the efficacy of these standard therapies without increasing the burden of side effects for the patient.
Based on our encouraging early clinical data, IMM-101 will be pursued in several cancer indications combining IMM-101 with one or more of these major pillars of cancer treatment. We are strongly focused on developing IMM-101 for the treatment of Pancreatic cancer. Our planned approach to this cancer is very comprehensive. With the proposed Immodulon study and investigator sponsored studies we are aiming to investigate IMM-101 in the three most advanced stages of this disease affecting about 80% of the patients with Pancreatic cancer, of which all currently have a poor prognosis.